Invivyd logo
Invivyd
IVVD | NASDAQ
Chart Builder DCF Calculator
$0.54
-$0.04 (-7.23%)
At close: Nov 16, 2026, 4:00 PM ET
$0.56
+$0.02 (+3.67%)
After-hours: Nov 16, 2026, 7:54 PM ET

Invivyd Company Profile

Company profile explained

Company Profile

Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.

Key Executives

Name Position
Marc William Elia CEO & Chairperson of the Board
Jill Andersen Chief Legal Officer & Corporate Secretary
Julie Green Chief Human Resources Officer
Katie Falzone Senior Vice President of Finance
Kristie Coneys Kuhl Chief Communications Officer
Michael J. Mina Chief Medical Officer & Chief Epidemiologist
Rachael Gerlach Senior Vice President of Regulatory Affairs
Robert D. Allen Chief Scientific Officer
Timothy Lee Chief Commercial Officer
William E. Duke Jr. CFO and Principal Financial & Accounting Officer

Latest SEC Filings

Date Type Title
Sep 29, 2026 8-K Current Report
Sep 02, 2026 4 Filing
Sep 02, 2026 3 Filing
Sep 01, 2026 4 Filing
Sep 01, 2026 8-K Current Report
Aug 18, 2026 4 Filing
Aug 18, 2026 4 Filing
Aug 18, 2026 4 Filing
Aug 18, 2026 4 Filing
Aug 18, 2026 4 Filing
View All SEC Filings ➞
Invivyd
Invivyd logo
Country United States
IPO Date Aug 6, 2021
Industry Biotechnology
Sector Healthcare
Employees 122
CEO Marc William Elia

Contact Details

209 Church Street New Haven, Connecticut 06510 United States

Stock Details

Ticker Symbol IVVD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001832038
CUSIP Number 00534A102
ISIN Number US00534A1025
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.